Navigation Links
NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
Date:10/25/2007

ned from Dawson James Securities, Inc., Attn: Investment Banking, 925 South Federal Highway, 6th Floor, Boca Raton, FL 33432, telephone number (866) 928-0928. Copies of the Canadian prospectus may be obtained from Dundee Securities Corporation, 1 Adelaide St. E., Suite 2700, Toronto, Ontario M4T 1J9; Attn: Equity Capital Markets, E-mail: ecm@dundeesecurities.com.

About NovaBay

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus (MRSA). NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus and in contact lens solutions and a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay's NeutroPhase product in woundcare applications.

NovaBay(TM), Aganocide(TM) and NeutroPhase(TM) are trademarks of NovaBay Pharmacuticals, Inc. All other trademarks and trade names are the property of their respective owners.

Safe Harbor Statement

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the mar
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Corn prices and ethanol: Are the markets flaky - or working as they should?
4. Alliant to add 100 megawatts of wind power by 2005, raise gas prices
5. QBIs PreserveX product passes initial test
6. 2006: A great biotech financing year, unless you were going public!
7. TomoTherapys 100th radiology system reaches public sector
8. With patents and research tools, when is private really public?
9. Brady Corp. raises $137 million in public offering
10. In public attitudes about taxes and spending, Wisconsin is Jekyll and Hyde
11. Republican sees nothing wrong with Doyles use of executive order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... February 28, 2015 Increasing its efforts to ... launches its first three episodes of The GMO TRUTH podcast ... this month, as it continues its mission to discover the ... project's first phase, to “uncover the truth about the GMOs ... , The GMO Truth Podcast is an expansion of the ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... financial results for the quarter,ended March 31, 2008., ... net revenue of,$372.2 million compared to net revenue of ... increase was primarily due to increased,product and service revenue ...
... dynamic stabilization,nonfusion segments skyrocketed, according to Millennium Research Group,s US ... ... Millennium Research Group,s,(MRG) US Spine Marketrack(TM) results indicate that ... and surgeon,awareness and new product releases starting in Q3 2007 ...
... will be enrolled to evaluate R7128 1500mg BID in HCV,genotypes 2 and 3 prior ... ... 1:00 PM ET (US) ... CEST (Milan) --, PRINCETON, N.J. and MILAN, Italy, April 24 ,Pharmasset, Inc. (Nasdaq: ...
Cached Biology Technology:Inverness Medical Innovations Announces First Quarter 2008 Results 2Inverness Medical Innovations Announces First Quarter 2008 Results 3Inverness Medical Innovations Announces First Quarter 2008 Results 4Inverness Medical Innovations Announces First Quarter 2008 Results 5Inverness Medical Innovations Announces First Quarter 2008 Results 6Inverness Medical Innovations Announces First Quarter 2008 Results 7Inverness Medical Innovations Announces First Quarter 2008 Results 8Inverness Medical Innovations Announces First Quarter 2008 Results 9Inverness Medical Innovations Announces First Quarter 2008 Results 10Adoption of Spinal Nonfusion Technologies Doubled in One Year 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 3Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 4Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 5
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... standing member of the IOF Board and leading researcher ... the recipient of the prestigious Pierre Delmas Award. The ... Osteoporosis & Osteoarthritis (ESCEO13-IOF), currently being held in Rome, ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ...
... the University of Alberta are abuzz after using fruit ... caffeine,s lethal effects on cancer cellsresults that could one ... Previous research has established that caffeine interferes with ... finding that has generated interest in using the stimulant ...
... past, now has had its genome sequenced, providing a ... the adaptation from an aquatic environment to land. A ... Director of Molecular Genetics at the Benaroya Research Institute ... the University of Washington, will publish "The African coelacanth ...
Cached Biology News:Pierre Delmas Award presented in Rome to Professor Socrates Papapoulos 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 3
... the macro- and micronutrients as ... (1962) and the vitamins as ... (1968). Preparation Quantity Equivalency: Formulated ... powder per liter of medium. ...
... Total Canine Endostatin. Canine Cytokine ... products include a line of enzyme-linked ... reagents used for multiple research applications. ... are ultra-sensitive, quick and dependable assays. ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... Biosystems and MDS Sciex present the ... high performance hybrid triple quadrupole/linear ion ... discovery, drug development or proteomics researcher. ... from the leaders in mass spectrometry ...
Biology Products: